Needham analyst Serge Belanger maintained a Buy rating on Phasebio Pharmaceuticals (PHAS – Research Report) today and set a price target of $8.00. The company’s shares closed today at $1.20.
Belanger covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Cytokinetics, and Amphastar Pharmaceuticals. According to TipRanks, Belanger has an average return of 7.7% and a 46.55% success rate on recommended stocks.
Phasebio Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $13.00.
See today’s best-performing stocks on TipRanks >>
PHAS market cap is currently $58.92M and has a P/E ratio of -0.51.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PhaseBio Pharmaceuticals, Inc. is engaged in the development and commercialization of biotherapeutics for the treatment of orphan diseases. It focuses on cardiopulmonary disorders. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.
Read More on PHAS:
- Hour Loop Reports Second Quarter 2022 Results
- Analysts Offer Insights on Healthcare Companies: Knight Therapeutics (OtherKHTRF) and Phasebio Pharmaceuticals (PHAS)
- Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
- OneWater Marine Announces the Appointment of Steve Roy to its Board of Directors
- Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
